Event Details:
Wednesday, January 23, 2019
This Event Has Passed
Time
7:30pm to 7:30pm PST
Location
Davos, Switzerland
Part of Series
Image
![](/sites/default/files/styles/scale_and_crop_75_68_sm_x2/public/32976284488_f54f4804ba_o.jpg?itok=IWkvqG_j)
Carolyn Rodriguez
Department of Psychiatry and Behavioral Sciences
Stanford University
Background
Low doses of ketamine seem able to dramatically improve obsessive-compulsive disorder, which has so far proved hard to treat. Carolyn Rodriguez’s lab at Stanford is seeking to understand how it works, with the hope of developing next-generation treatments that do not have ketamine’s side effects.